Name of journal: World Journal of Diabetes

Manuscript NO: 88728

Title: Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLR inflammasome

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 02446061

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Full Professor, Research Scientist

Reviewer’s Country/Territory: Mexico

Author’s Country/Territory: China

Manuscript submission date: 2023-10-08

Reviewer chosen by: Yu-Lu Chen

Reviewer accepted review: 2023-11-07 14:10

Reviewer performed review: 2023-11-13 00:56

Review time: 5 Days and 10 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Novelty of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
<th>[ ] Grade D: No novelty</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Creativity or innovation of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
<th>[ ] Grade D: No creativity or innovation</th>
</tr>
</thead>
</table>
SPECIFIC COMMENTS TO AUTHORS
The manuscript has interesting content. However some points should be edited: a) The entire manuscript requires proofreading. Some mistakes of grammar, typing, punctuation should be avoided. Also check abbreviations and units of measurement. b) The discussion is brief. It could be enriched with the effect of similar compounds (references could be more than 35 at least). Also, Please check some recent articles closely linked to your work and discuss about your observations and that reported on them. For example: - Akashi N, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y, Sakakura K, Wada H, Momomura SI, Fujita H. Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. Diabetes Metab Syndr Obes. 2023 Apr 13;16:1043-1054. doi: 10.2147/DMSO.S403125. PMID: 37077576; PMCID: PMC10108873. c) Conclusions, limitation and prospective studies, as well as implications in Diabetes treatment should be clearly sentenced in the manuscript.
**RE-REVIEW REPORT OF REVISED MANUSCRIPT**

**Name of journal:** *World Journal of Diabetes*

**Manuscript NO:** 88728

**Title:** Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLR inflammasome

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 02446061

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Full Professor, Research Scientist

**Reviewer’s Country/Territory:** Mexico

**Author’s Country/Territory:** China

**Manuscript submission date:** 2023-10-08

**Reviewer chosen by:** Cong Lin

**Reviewer accepted review:** 2023-12-21 02:13

**Reviewer performed review:** 2023-12-21 02:25

**Review time:** 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: Anonymous</td>
<td>Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
The comments AND suggestions have been addressed.